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Introduction
Chemotherapy in cancer treatment is often limited by 
the toxicity of the anti-cancer drugs used. This is because 
both the target cancerous cells and normal cells are non-
selectively exposed to the drug, which can lead to un-
wanted toxic side-effects. Therefore, various drug carriers 
such as soluble polymers (Janes et al., 2001; Vandamme 
et al., 2002), polymeric nanoparticles (Chawla & Amiji, 
2002; Lemarchand et al., 2004; Yun & Lee, 2005; Gryparis 
et al., 2007), and liposomes (Park, 2002; Medina et al., 
2004) have been investigated in an attempt to increase 
the therapeutic efficacy and to reduce the toxicity of anti-
cancer drugs. Among these systems, the role of natural 
polysaccharides in developing controlled drug delivery 
systems has increased significantly and pullulan is gaining 
lots of attraction towards this application. This is mainly 
due to its non-toxic, non-immunogenic, and biodegrad-
able properties (Drobe et al., 1997). Pullulan consists of 
1–4 and 1–6 glycosidic linkages and is a water-soluble, 
neutral, linear polysaccharide that cannot self-associate 
in aqueous solutions due to its solubility in water. So, in 
any case hydrophobic pullulan derivatives were used 
as drug delivery carriers (Akiyoshi et al., 1999; Jeong 
et al., 1999; Na & Bae, 2002; Na et al., 2003a and b). These 
hydrophobic pullulan derivatives self-associate to form 
colloidally stable nanoparticles with inner hydrophobic 
core in water. This hydrophobic core can encapsulate 
hydrophobic substances like insoluble drugs, DNA, and 
proteins. The objective of these works was to develop a 
versatile carrier system for gene and drugs transfer into 
mammalian cells.
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Abstract
The purpose of this work was to develop a novel nano-carrier with targeting property to tumor. In this study, 
pullulan acetate (PA) was synthesized by the acetylation of pullulan to simplify the preparation technique 
of nanoparticles. Folic acid (FA) was conjugated to PA in order to improve the cancer-targeting activity. The 
products were characterized by proton nuclear magnetic resonance (1H NMR) spectroscopy. Epirubicin-
loaded nanoparticles were prepared by a solvent diffusion method. The loading efficiencies and EPI content 
increased with the amount of triethylamine (TEA) increasing in some degree. FPA nanoparticles could incor-
porate more epirubicin than PA nanoparticles. The folate-modified PA nanoparticles (FPA/EPI NPs) exhibited 
faster drug release than PA nanoparticles (PA/EPI NPs) in vitro. Confocal image analysis and flow cytometry 
test revealed that FPA/EPI NPs exhibited a greater extent of cellular uptake than PA/EPI NPs against KB cells 
over-expressing folate receptors on the surface. FPA/EPI NPs also showed higher cytotoxicity than PA/EPI 
NPs. The cytotoxic effect of FPA/EPI NPs to KB cells was inhibited by an excess amount of folic acid, suggest-
ing that the binding and/or uptake were mediated by the folate receptor.
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To solve the problem of site-specific targeting for 
the colloidal systems, some authors have attempted to 
increase the tissue specificity of colloidal drug carriers by 
coupling targeting agents. Among the possible targeting 
agents, folic acid could be exploited to realize delivering 
drugs into cancer cells. Folic acid (FA) is an essential vita-
min whose receptor is over-expressed in various human 
cancers, including malignancies of the ovary, uterus, 
breast, kidney, lung, head and neck, brain, and myeloid 
cancers (Weitman et al., 1992a; Weitman et al., 1992b; 
Ross & Chaudhuri, 1994; Toffoli et al., 1997; Bueno et al., 
2001). Folate receptor (FR) is a 38–40 kDa glycosyl-phos-
phatidylinositol-anchored glycoprotein with a high affin-
ity for folic acid (Antony, 1996). Tumor-selective targeting 
carriers have been achieved by combining folic acid with 
liposomes (Lee & Huang, 1996; Goren et al., 2000; Pan 
et al., 2003), nanoparticles (Stella et al., 2000; Zhang 
et al., 2004), and micelles (Yoo & Park, 2004; Liu et al., 
2007). The drug delivery system (DDS) endocytosed via 
a vitamin receptor-mediator inter-action could constitute 
a more protected pathway for intracellular delivery and 
could release the drug over a longer period to the endo-
some, without being rapidly delivered to the lysosomes.
The purpose of the present study was to combine the 
advantages of hydrophobic pullulan derivatives with folic 
acid and fabricate a novel tumor targeted nano-carrier. In 
this study, pullulan acetate (PA) was synthesized to sim-
plify the preparation technique of nanoparticles. Then 
folic acid was conjugated with PA to improve the cancer 
targeting activity and internalization of nanoparticles. 
The nanoparticles were prepared by solvent diffusion 
method and their physicochemical characteristics were 
examined by transmission electron microscopy (TEM) 
and dynamic light scattering (DLS). Epirubicin (EPI) 
used as a model anti-cancer drug was incorporated into 
the nanoparticles. EPI release in vitro was studied at 
phosphate buffered saline (PBS, pH 7.4). Cellular uptake 
and in vitro cytotoxicity of free EPI and EPI-loaded nano-
particles made from pullulan derivative against KB cells 
were investigated.
Materials and methods
Materials
Pullulan (Mw = 200,000) was purchased from the 
Hayashibara Co. (Japan). Folic acid, poly (vinyl alco-
hol), 4-Dimethylamino-pyridine, and 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5 -diphenyltetrazolium bromide 
(MTT) were purchased from Sigma (St. Louis, MO). 
Epirubicin·hydrochloride was supplied from Hisun 
Pharmaceutical Co., Ltd. (Zhejiang, PR China). N, 
N’-Dicyclohexylcarbodiimide was purchased from 
Shanghai Medpep Co., Ltd (Shanghai, PR China). RPMI-
1640 medium without folic acid was obtained from 
Gibco (Gibco Co. Uxbridge, UK). KB cell line was pur-
chased from ATCC. All other chemicals were of analytical 
grade.
Acetylation of pullulan
PA, as hydrophobized pullulan, was synthesized as fol-
lows (Jung et al., 2003): 2 g of pullulan, suspended in 
20 ml of formamide, was dissolved by vigorous stirring 
at 54°C. To this solution, pyridine (6 ml) and 7.5 ml of 
acetic anhydride were then added. The mixture was 
stirred at 54°C for 48 h. A dark-brown precipitate was 
thus obtained and purified by re-precipitation with 
1000 ml of distilled water and 500 ml of methanol. The 
solid material was vacuum-dried for 24 h, and a white 
powder was obtained. The degree of substitution (DS) 
of PA was determined by 1H NMR method (Naozumi & 
Mitsuhiro, 2006).
Synthesis of folate modified PA (FPA)
FA was coupled to PA by N, N’-Dicyclohexylcarbodiimide 
(DCC) and 4-Dimethylamino-pyridine (DMAP) medi-
ated ester formation. The carboxyl groups of FA (1 g) in 
dried DMSO were activated by adding DCC (700 mg) and 
DMAP (200 mg); 0.8 g activated FA was added to 20 ml of 
dried DMSO containing 1 g of PA and reacted for 72 h at 
room temperature. After 72 h, the reactant mixture was 
filtered to remove byproduct. This process was repeated 
three times for 24 h. To completely remove the non-re-
actants, the supernatant was precipitated in methanol, 
then centrifuged to separate the precipitated FPA and 
washed thoroughly with methanol. The precipitated pel-
let was suspended and dialyzed against 5 mM carborate/
bicarbonate buffer (pH 10.0) for 48 h using a dialysis tube 
(molecular cut-off 12,000), then dialyzed against distilled 
water for 72 h. The buffer or distilled water was exchanged 
at 3–6 h intervals. The precipitated FPA was retrieved by 
filtration and lyophilized to give a yellow powder. The DS 
of FPA was determined by UV/Vis spectrophotometry in 
DMSO at 285 nm.
Characterization of the synthesized polymers
The polymers were characterized by proton nuclear mag-
netic resonance (1H NMR) spectra, which were recorded 
on a Varian Inova spectrometer (USA) at 500 MHz, and 
d-DMSO was used as the solvent.
Nanoparticles preparation and drug loading
Nanoparticles were prepared according to a solvent dif-
fusion method (Fessi et al., 1989; Govender et al., 1999; 
Bilati et al., 2005). The procedure was as follows: PA or 
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FPA (50 mg) was accurately weighed and dissolved in 
DMF (5 ml). Epirubicin hydrochloride (EPI·HCl, 5 mg) 
was dissolved in DMF (1 ml) and added by triethylamine 
(TEA) to remove hydrochloride. The solution was mixed 
with PA or FPA solution after stirring in the dark for 
12 h, keeping the drug/polymer ratio constant at 1/10 
(w/w). The mixed solution was then added to an aque-
ous solution of 0.5% (w/w) poly (vinyl alcohol) (PVA, 
44 ml) by means of a syringe positioned with the needle 
directly in the medium under moderate magnetic stir-
ring. The freshly formed nanoparticles were filtered (1 
μm filters) and then subjected to ultracentrifugation 
(Avanti J-25, Beckman, USA) at 18,000 rpm for 20 min 
at 4°C to remove free drug, DMF, and PVA. The pellet 
was re-dispersed in distilled water. EPI-loaded nano-
particles were dissolved in a mixture of DMSO/H
2
O 
(9/1, w/w). The amount of EPI incorporated into PA or 
FPA nanoparticles was determined by a UV/Vis spec-
trophotometer (Spectramax plus384, Micromolecular, 
USA) at 485 nm.
Transmission electron microscopy (TEM) 
examinations
The morphologies of PA and FPA nanoparticles were 
analyzed by TEM (JEM-100CXII, Jeol, Japan). Several 
drops of the freshly prepared nanoparticles solution con-
taining 0.02 (w/v)% phosphotungstic acid were placed 
on a copper grid coated with carbon film, and air-dried 
at room temperature. The observations were carried out 
with an electron kinetic energy of 80 kV.
Dynamic light scattering measurement
Size and size distribution of the prepared nanoparticles 
were determined by dynamic light scattering (DLS, BI-90 
plus, Brookhaven Ins., NY, USA) using an argon ion laser 
beam at a wavelength of 488 nm and a scattering angle of 
90°. Each measurement was repeated five times. Before 
measurement, the particle suspension was appropriately 
diluted.
Drug release rate measurements
The freshly prepared drug loaded nanoparticles were 
diluted to 1 mg/ml for polymer concentration. The 
diluted solutions (2 ml) were transferred to dialysis 
membrane tubes with MWCO of 10,000 Da. The dialysis 
tube was then immersed in a beaker containing 10 ml of 
0.1 M PBS (pH 7.4), which were shaken at a speed of 100 
rev/min, and incubated at 37°C. At specific time intervals, 
the whole medium was removed and replaced by fresh 
PBS so as to maintain a sink condition. The amount of 
EPI in the solution was analyzed by UV/Vis spectroscopy 
at 485 nm.
Cell culture
KB cells, a human nasopharyngeal epidermal carcinoma 
cell line over-expressing FR (Sadasivan & Rothenberg, 
1989), were cultured in T-25 flasks at 37°C in a humidified 
atmosphere containing 5% CO
2
 using folate-free RPMI-
1640 supplemented with 5% penicillin–streptomycin and 
10% heat-inactivated fetal calf serum. The only source of 
folic acid in the media was due to the presence of the 10% 
fetal calf serum.
Confocal image analysis
EPI accumulated in KB cells was localized using a con-
focal laser scanning microscope (FV1000, Olympus, 
Japan). The KB cells (2 × 105 cells/ml) were seeded on 
MatTek culture dishes for 24 h and then treated with free 
EPI or EPI incorporated nanoparticles. The concentra-
tion of EPI was ca. 10 mg/L. After incubation for 2 h, cells 
were thoroughly washed with PBS solution. Microscopic 
visualization of live cells was done in new medium. For 
EPI, maximum excitation was performed by a 488-nm 
line of internal argon laser, and fluorescence emission 
was observed above 515 nm with long-pass barrier filter 
LP-515.
Flow cytometry
KB cells (2 × 106 cells/well) were seeded in 6-well plates. 
After 24 h, the cells were incubated with free EPI and EPI 
incorporated nanoparticles at a final EPI concentration of 
10 mg/L for 2 h at 37°C. The cells were thoroughly washed 
with PBS, then released from the plates with trypsin treat-
ment and pelleted (600 g) twice. The cells were examined 
on a FACScalibur flow cytometer (Becton-Dickinson Ins., 
NJ, USA). Twenty thousand cells (gated events) were 
counted for each sample, and EPI fluorescence was 
detected with logarithmic settings (FL2; Em = 575 nm). 
Cells were counted as positive if their fluorescence (FL2) 
was higher than that of 95% of cells from an untreated 
cell suspension.
Cytotoxicity test
KB cells (5 × 104 cells/ml) harvested from growing cells 
as a monolayer were seeded onto 96-well plates at 
10,000 cells per well, and incubated for 24 h. Free EPI 
and EPI-loaded nanoparticles made from FPA and PA 
were dissolved and diluted in folate-free RPMI 1640 
growth medium to give final EPI concentrations of 0.01, 
0.1, 0.5, 1, 1.25, 2.5, 5, and 10 mg/L. The drug free poly-
mer nanoparticles in RPMI 1640 were diluted to 250, 
500, 1000, and 2000 mg/L. The media in the wells were 
replaced with 100 μl of the pre-prepared samples con-
taining blank nanoparticles or EPI-loaded nanoparticles. 
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The EPI and EPI-loaded nanoparticles solutions were 
removed after 2 h of incubation. Upon removal of the 
drug solutions, the cells were then washed once with 
100 μl of PBS solution, and incubated with fresh RPMI 
1640 and maintained in 5% CO
2
, at 37°C for 46 h. Fresh 
growth media (90 μl) and 10 μl aliquots of MTT solution 
(5 mg/ml) were used to replace the mixture in each well 
after 46 h. The plates were then returned to the incu-
bator and maintained in 5% CO
2
, at 37°C for a further 
4 h. The growth medium and excess MTT in each well 
were then removed. DMSO (150 μl) was then added to 
each well to dissolve the internalized purple forma-
zan crystals. Each sample was tested in six replicates 
per plate. Three plates were used, making a total of 18 
replicates sample. The UV absorbance at 570 nm was 
measured using a micro-plat reader (Spectramax plus 
384, Micromolecular, USA). The results were expressed 
as a percentage of the absorbance of the non-treated 
cells.
Folate competition study
KB cells were cultured with the same conditions as that 
for the cytotoxicity tests, and seeded onto 96-well plates 
at 10,000 cells density per well, and incubated for 24 h 
upon seeding. A stock solution containing FPA/EPI nano-
particles was prepared at EPI concentration of 2.5 mg/L. 
Another stock solution containing 4400 mg/L of free folic 
acid was also prepared using 2% NaCO
3
 and filtered with 
a 0.22 μm pore-size filter. A series of dilutions was then 
performed on the stock solution containing free folic 
acid to reach final concentrations of 137.5, 275, 550, 
1100, 2200, and 4400 mg/L. The pre-prepared EPI-loaded 
nanoparticles solution and the diluted free folic acid 
solutions were subsequently mixed at 9:1 to obtain drug 
solutions containing 2.5 mg/L of EPI and 13.75, 27.5, 55, 
110, 220, and 440 mg/L of free folic acid, respectively. 
Equal volume of the 2.5 mg/L EPI-loaded nanoparticles 
solution was also mixed with pure growth medium to 
obtain drug solution with only 2.5 mg/L EPI in it. The 
seeded cells were then incubated at 37°C with 100 μl 
of the drug solutions for 2 h under the presence of 5% 
CO
2
. Following that, the cells were then washed once 
with PBS solution, and further incubated with fresh 
growth medium and maintained in 5% CO
2
, at 37°C for 
46 h. The cell viability after incubation with the drug 
solution was then assessed using the same MTT assay 
as above.
Statistical analysis
Statistical analysis was performed by Student’s t-test for 
two groups. All results were expressed as the mean ± SD 
unless noted exceptionally, a probability (p) of less than 
0.05 is considered statistically significant.
Results and discussion
Synthesis and characteristics of PA and FPA
The sample of PA, showed by Figure 1, comprising 2.7 
acetyl groups per 1 anhydroglucose unit of pullulan, 
was synthesized to facilitate the preparation of nano-
particles. Then PA was esterified by folic acid to target 
to FR over-expressed tumor cells. Figure 2 shows typical 
1H NMR spectra of PA and FPA in DMSO-d
6
. Hydroxyl 
proton signals, observed at 4.5–5.6 ppm in the 1H NMR 
spectrum of pullulan (Figure 2a), decreased, and methyl 
proton signals at 1.8–2.2 ppm, which are assigned to the 
acetyl groups, appeared in the 1H NMR spectrum of the 
PA (Figure 2b). Some methine proton signals of pullu-
lan shifted to lower magnetic field by acetylation. These 
results indicate that acetylation certainly proceeded 
(Zhang et al., 2009).
The linkage of FA with PA was confirmed by the pres-
ence of signals at δ 6.75–8.77 ppm (Figure 2c). 6.75 ppm 
(d, J = 7 Hz, 3’, 5’ H of FA group), 7.63 ppm (d, J = 7 Hz, 
2’, 6’ H of FA group), 8.77 ppm (s, C7-H of FA group) in 
the 1H NMR spectrum of FPA. Moreover, some methine 
proton signals of FA shifted to higher magnetic fields due 
to γ-carboxylic acid of FA was conjugated with hydroxyl 
group of PA. The content of FA in the conjugates was 6–8 
per 100 anhydroglucose units of PA, determined by UV/
Vis (DMSO) at 285 nm.
Solubility of pullulan and its derivates was varied. 
Pullulan was soluble in water and organic solvent, e.g. 
DMSO, DMF, and pyridine. After acetylation, PA was 
insoluble in water, but readily soluble in mostly organic 
solvents except for alcohols. Compared with PA, FPA was 
insoluble in acetone and THF, which attributed to the 
higher hydrophilicity and/or polarity of folic acid.
Characterization of PA or FPA nanoparticles and  
drug loading
PA and its modified materials have been investigated 
for their possible utility as a drug delivery carrier, due to 
its favorable biocompatibility and solubility in a variety 
of organic solvents (Jung et al., 2003; Na et al., 2003a; b; 
2004). The nanoparticles were prepared by the diafiltra-
tion method in the literature. In the present paper, the 
solvent diffusion method was used to prepare PA and FPA 
nanoparticles. This technique is a straightforward tech-
nique. Nanoprecipitation occurs by a rapid desolvation 
of the polymer when the polymer solution is added to the 
non-solvent. Indeed, as soon as the polymer-containing 
solvent has diffused into the dispersing medium, the 
polymer precipitates, involving immediate drug entrap-
ment (Murakami et al., 1999; Bilati et al., 2005).
The morphological structures of PA and FPA nano-
particles were observed using TEM and the size and 
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size distributions in distilled water were measured by 
DLS, as shown in Figure 3. The prepared nanoparticles 
were found of spherical shape. The mean diameter of PA 
nanoparticles was 185.7 ± 10.1 nm, and FPA nanoparticles 
with a folic acid DS of 7.5 was 261.2 ± 33.7 nm. The par-
ticle size of FPA nanoparticles was larger than PA due 
to the increase in the swelling capacity resulting from 
the hydrophilic property of folic acid. The diameter of 
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Figure 1. Chemical structures of a repeat unit of PA and folic acid.
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Figure 2. 1H NMR spectra of (a) pullulan, (b) PA, and (c) FPA in DMSO-d
6
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nanoparticles observed by TEM was smaller than those 
obtained by DLS, owing to the diameter obtained by DLS 
reflected the hydrodynamic diameter of nanoparticles, 
which swelled in aqueous solution.
The solvent diffusion method is mostly suitable for 
entrapment compounds having a hydrophobic nature 
which is soluble in ethanol, acetone, or other water-
miscible organic solvents, but displays very limited solu-
bility in water (Bilati et al., 2005). EPI·HCl is hydrophilic 
due to the protonated form of its amino groups. To 
obtain a high amount of EPI incorporation into the 
nanoparticles, non-ionized free amine EPI form may be 
necessary. TEA of 1∼3-times equivalent to the EPI·HCl 
quantity was added to the organic solvent before prepa-
ration of nanoparticles to remove hydrochloride from 
EPI·HCl. As shown in Table 1, for PA nanoparticles, the 
incorporated quantity of EPI increased with the level of 
TEA addition. This was most likely due to the change 
of drug ionization. When EPI·HCl was encapsulated 
within PA nanoparticles without using TEA, little EPI 
(0.01% w/w) was incorporated into nanoparticles, owing 
to the hydrophilicity of its protonated form. When TEA 
addition ratio increased, the removal of hydrochloride 
from EPI·HCl was promoted, therefore, the higher 
hydrophobicity of EPI was considered to allow physical 
entrapment in a more efficient manner by hydrophobic 
interaction (Fukashi et al., 2002). Compared with PA, 
FPA nanoparticles could entrap more EPI when TEA 
was added less than 2-times equivalent to the EPI·HCl 
quantity. The reason might be that the polymer’s nature 
had changed due to the introduction of folic acid. In the 
following experiments, TEA of 2.0-times equivalent to 
the EPI·HCl quantity was added in view that the overdos-
age of TEA would inactivate of EPI.
At the same time, due to the incorporation of drug, 
the interaction of polymer molecules was decreased. 
Therefore, the average effective diameter of drug loaded 
nanoparticles was increased, with drug contents increas-
ing both PA and FPA nanoparticles.
In vitro drug release
Figure 4 showed the in vitro release profiles of EPI from 
PA and FPA nanoparticles, which exhibited a biphasic 
release pattern characterized by an initial burst of ∼ 
36.8 ± 2.2% and 45.4 ± 2.5% of the total entrapped EPI 
in the nanoparticles at 6 h. It was mainly due to the 
release of some part of drug, which was absorbed onto 
the surface of nanoparticles or loosely encapsulated in 
the hydrophilic domain. The initial burst is followed 
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Figure 3. Transmission electron micrograph photographs and size distribution (a) PA and (b) FPA.
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by a slow, sustained release. The total amount of drug 
released from PA and FPA nanoparticles over 72 h were 
51.6 ± 5.1% and 90.8 ± 1.8%, respectively. The increased 
release rate of FPA nanoparticles was attributed to the 
higher hydrophilicity, owing to introduction of folate. 
The release medium could easily access the core of the 
nanoparticle and increase the release rate.
Cellular accumulation studies in KB cells
Confocal microscopy was performed to compare uptake 
of free EPI, PA/EPI NPs, and FPA/EPI NPs using KB cells 
in the folate absence incubation medium. As shown in 
Figure 5, when free EPI was incubated with KB cells for 
2 h, epirubicin molecules were transported into the cells 
through a passive diffusion pathway, and mainly accu-
mulated in the nucleus (Figure 5a). However, fluores-
cence was observed in the cytoplasm when the cells were 
incubated with PA/EPI NPs at the same time (Figure 5b). 
This finding indicates that PA/EPI NPs were internalized 
by the cells through an endocytosis process, and then 
escaped from the endosomes and/or the lysosomes 
to enter the cytoplasm (Panyam & Labhasetwar, 2003; 
Breunig et al., 2008). In contrast, strong fluorescence 
was observed in the cytoplasm as well as the nucleus 
when the cells were incubated with the EPI-loaded 
FPA nanoparticles (FPA/EPI NPs). The strong signals 
that appeared in the nucleus were attributed to the EPI 
molecules released from the nanoparticles. This may be 
attributed to the fact that drug release from FPA/EPI NPs 
was much faster than PA/EPI NPs. However, it seems that 
an equivalent amount of drug is released from PA and 
FPA nanoparticles within the first 4 h in vitro (Figure 4). 
The process of drug release from nanoparticles in cells 
was different from in vitro, which was demonstrated by 
our previous research (Zhang et al., 2009).
Cellular uptake extents of free EPI and EPI-loaded 
nanoparticles by KB cells were also evaluated by flow 
cytometry analysis, as was shown in Figure 6. There was 
a little difference in cellular uptake of EPI between free 
EPI and PA/EPI NPs. However, when KB cells were incu-
bated with FPA/EPI NPs, much greater cellular uptake 
of EPI was observed in the folate-free medium. The flow 
cytometry results confirmed that FPA/EPI NPs could be 
targeted to cancer cells over-expressing folate receptors 
on their surface. Employing folate as a targeting moiety 
Table 1. Particle size and drug-loading contents against various TEA/ EPI molar ratio (n = 3).
TEA/EPI (mol/mol)
PA FPA
Drug entrapment 
(wt%) Drug content (wt%) Diameter (nm)
Drug entrapment 
(wt%) Drug content (wt%) Diameter (nm)
0/1 1.0 ± 0.01 0.01 ± 0.001 195.4 ± 5.4 15.92 ± 2.81 1.57 ± 0.28 257.4 ± 5.4
1/1 7.9 ± 1.21 0.78 ± 0.08 209.2 ± 10.3 55.43 ± 1.94 5.25 ± 0.18 357.9 ± 29.5
2/1 54.4 ± 2.93 5.16 ± 0.27 284.3 ± 21.5 71.32 ± 1.81 6.65 ± 0.16 387.5 ± 36.2
3/1 64.8 ± 1.73 6.09 ± 0.20 347.9 ± 38.5 46.52 ± 0.53 4.44 ± 0.04 321.4 ± 13.7
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Figure 4. EPI release from PA and FPA nanoparticles at 37°C (PBS, pH 7.4).
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was widely studied in various delivery vehicles, especially 
liposomes for anti-cancer therapy. In the present study, 
polymeric nanoparticles with a targeting moiety were 
utilized as an alternative EPI delivery vehicle, circum-
venting the instability concern occurring in most cases 
of liposomes.
Cellular cytotoxicity
KB cells grown in 96-well plates were exposed to serial 
dilutions of EPI-loaded nanoparticles or free EPI for 2 h, 
and cell viability was determined by the MTT assay fol-
lowing 46 h further incubation, as described earlier. EPI 
concentrations leading to 50% cell killing (IC
50
) were 
determined from concentration-dependent cell viabil-
ity curves. According to the data obtained, even after 
prolonged contact with the cells (4 h), the drug free PA 
or FPA nanoparticles exhibited low cytotoxicity up to 
2 mg/ml.
Cell cytotoxicities of EPI, PA/EPI NPs, and FPA/EPI NPs 
against KB cells were investigated. EPI concentrations 
leading to 50% cell-killing (IC
50
) were determined from 
concentration-dependent cell viability curves. As shown 
in Figure 7, FPA/EPI NPs (IC
50
 = 1.12 mg/L) exhibit supe-
rior cytotoxic activities to PA/EPI NPs (IC
50
 = 2.75 mg/L). 
This reveals that folate moieties in FPA nanoparticles 
played an important role in exerting a cytotoxic effect by 
binding of FPA/EPI NPs with folate receptors on KB cells 
and subsequently increasing their intracellular uptake as 
a result of the receptor-mediated endocyctosis. In con-
trast to EPI-loaded nanoparticles, free EPI showed less 
cytotoxicity against KB cell line (IC
50
 = 3.92 mg/L), which 
result from the reduced cellular uptake of EPI, stressing 
the key role of nanoparticles binding and internalization 
in enhancement of cytotoxic activity.
Folate competition
In order to further evaluate the role of folate in the cellular 
uptake of FPA/EPI NPs, KB cells were incubated with the 
nanoparticles in RPMI 1640 medium containing increasing 
concentrations of free folate. The cytotoxicity of FPA/EPI 
NPs against KB cells was inhibited by excess-free folate, 
and the cell viability increased with increasing folate con-
centration (Figure 8). For instance, the cell viability of FPA/
EPI NPs was ∼ 33% at an EPI concentration of 2.5 mg/L, but 
it was ∼ 63% in the presence of 440 mg/L free folate. These 
findings suggested that free folate molecules prevented the 
cellular uptake of the nanoparticles by competitive bind-
ing to the folate receptors on the cell surface.
Conclusions
Bio-functional polymer folate-modified pullulan 
acetate was successfully synthesized and utilized to 
fabricate nanoparticles by a solvent diffusion method 
for targeted delivery of anti-cancer drugs. The prepara-
tion procedure was easy to be operated and practical 
for large-scale production. The nanoparticles were 
spherical in nature, and had a narrow size distribu-
tion. EPI incorporation behavior was substantially 
influenced by feed amounts of TEA. Drug release from 
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Figure 6. Flow cytometry profiles of fluorescence from cell-associated 
EPI. KB cells incubated with free EPI (green), PA/EPI NPs (red), FPA/
EPI NPs (blue) at an equivalent EPI concentration of 10 mg/L for 2 h 
at 37°C.
Figure 5. Confocal microscopic images of KB cells incubated with (a) free EPI, (b) PA/EPI NPs, (c) FPA/EPI NPs at an equivalent EPI concentra-
tion of 10 mg/L for 2 h at 37°C.
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FPA NPs was faster than PA. FPA/EPI NPs were taken 
up by folate receptor-expressing KB cells via the folate 
receptor-mediated endocytosis process. Greater uptake 
was observed when compared to PA/EPI NPs, resulting 
in enhanced cytotoxicity. Folate-conjugated pullulan 
acetate nanoparticles might be a potential targeted 
carrier to folate receptor over-expressing cancer cells. 
Further studies are in progress to test this new drug 
delivery system in vivo.
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